IQV:NYSE

IQVIA (IQV) is trading at $178.55, comfortably above the calculated support of $156.67 but still below its 20‑day SMA of $172.74 and far under the 50‑day SMA of $207.25, suggesting a near‑term price cushion. The RSI sits at 44.7, indicating neutral momentum, while the MACD histogram is positive (+3.19) and the MACD signal is bullish, hinting at a possible short‑term upside. Volatility is elevated at 63% over the past 30 days and the beta of ~1.15 points to higher-than‑market price swings, which aligns with the recent “decreasing” volume trend. Fundamentally, the stock appears undervalued: its trailing PE of 22.8 is below the industry average of 25.4, the forward PE contracts to 12.7, and the DCF‑derived fair value of $196.10 implies roughly 33% upside. Revenue growth of 10.3% and a solid ROE of 21% support a growth narrative, while operating cash flow of $2.65 bn and free cash flow of $2.22 bn demonstrate cash generation strength despite a high debt‑to‑equity ratio. Recent analyst sentiment is strongly positive, with TD Cowen upgrading to Buy and Barclays moving to Overweight, and the consensus 12‑month price target median sits at $240, reinforcing the upside thesis.
Actionable insight: The combination of technical bullish signals, a sizable valuation gap to DCF and analyst targets, and robust cash flow makes IQV a compelling buy for investors comfortable with moderate volatility, while the lack of dividend means returns will rely on price appreciation.